Regulation of Artificial Intelligence in Drug Discovery and Health Care
2020; Mary Ann Liebert, Inc.; Volume: 39; Issue: 5 Linguagem: Inglês
10.1089/blr.2020.29183.ks
ISSN1557-8704
AutoresKavita Sharma, Padmavati Manchikanti,
Tópico(s)COVID-19 diagnosis using AI
ResumoBiotechnology Law ReportVol. 39, No. 5 Original ArticlesRegulation of Artificial Intelligence in Drug Discovery and Health CareBy Kavita Sharma and Padmavati ManchikantiBy Kavita SharmaKavita Sharma is a doctoral fellow, and Padmavati Manchikanti is Professor and Dean, at Rajiv Gandhi School of Intellectual Property Law at the Indian Institute of Technology (IIT) in Kharagpur, West Bengal, India.Search for more papers by this author and Padmavati ManchikantiDr. Padmavati Manchikanti: E-mail Address: mpadma@rgsoipl.iitkgp.ac.inKavita Sharma is a doctoral fellow, and Padmavati Manchikanti is Professor and Dean, at Rajiv Gandhi School of Intellectual Property Law at the Indian Institute of Technology (IIT) in Kharagpur, West Bengal, India.Search for more papers by this authorPublished Online:7 Oct 2020https://doi.org/10.1089/blr.2020.29183.ksAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byAI under great uncertainty: implications and decision strategies for public policy7 September 2021 | AI & SOCIETY, Vol. 37, No. 4 Volume 39Issue 5Oct 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:By Kavita Sharma and Padmavati Manchikanti.Regulation of Artificial Intelligence in Drug Discovery and Health Care.Biotechnology Law Report.Oct 2020.371-380.http://doi.org/10.1089/blr.2020.29183.ksPublished in Volume: 39 Issue 5: October 7, 2020Online Ahead of Print:July 20, 2020Keywordsartificial intelligencedrug discoverydevice datahealth careregulationPDF download
Referência(s)